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Hypoxia-inducible factors (HIFs) have emerged in recent years as critical
regulators of immunity. Localised, low oxygen tension is a hallmark of
inflamed and infected tissues. Subsequent myeloid cell HIF stabilisation
plays key roles in the innate immune response, alongside emerging oxygen-
independent roles. Manipulation of regulatory proteins of the HIF tran-
scription factor family can profoundly influence inflammatory profiles,
innate immune cell function and pathogen clearance and, as such, has been
proposed as a therapeutic strategy against inflammatory diseases. The
direction and mode of HIF manipulation as a therapy are dictated by the
inflammatory properties of the disease in question, with innate immune cell
HIF reduction being, in general, advantageous during chronic inflamma-
tory conditions, while upregulation of HIF is beneficial during infections.
The therapeutic potential of targeting myeloid HIFs, both genetically and
pharmacologically, has been recently illuminated in vitro and in vivo, with
an emerging range of inhibitory and activating strategies becoming avail-
able. This review focuses on cutting edge findings that uncover the roles of
myeloid cell HIF signalling on immunoregulation in the contexts of inflam-
mation and infection and explores future directions of potential therapeutic
strategies.
Introduction
Hypoxia-inducible factors (HIFs) are master transcrip-
tional regulators of the cellular response to hypoxia,
that have influential roles in innate immune cell beha-
viour during inflammation and infections [1]. HIF
activity is tightly regulated, both at the transcriptional
and at the post-translational levels [2,3]. The major
point of control is regulation of protein degradation of
the HIF-a subunits. In normal oxygen conditions (nor-
moxia), the alpha subunits are hydroxylated by prolyl
hydroxylase domain (PHD) enzymes leading to
subsequent degradation by the proteasome (Fig. 1).
PHD enzymes require oxygen for their enzymatic
activity, and so when oxygen levels drop, PHDs
become inactive and HIF-a is stabilised, translocating
to the nucleus to form its transcription factor complex
that activates downstream genes. Multiple isoforms of
the alpha subunit (HIF-1a, HIF-2a and HIF-3a) con-
tribute to an extra level of regulatory complexity [4,5],
and while HIF-1a is the most widely characterised,
important roles of HIF-2a in immunity are emerging
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[6]. The HIF-3a gene is the least understood of the iso-
forms, with alternative transcriptional start and splice
sites contributing to different HIF-3a variants that can
have opposing functions [7]. Partially due to this com-
plexity, the roles of HIF-3a in immunity remain elu-
sive.
HIF researchers were awarded the Nobel Prize in
Physiology or Medicine in 2019 for their discoveries
on the regulation of the cellular hypoxia response,
with their medical research predominantly focusing on
HIFs’ potential role as a therapeutic target to combat
anaemia, due to HIF’s activating effect on red blood
cell production [8]. Other blood cells, especially those
of the myeloid lineage of innate immunity, are exqui-
sitely sensitive to HIF modulation, due to their adap-
tion to functioning in locations of low oxygen tension
(e.g. wounds or infected tissues) [9]. The effects of HIF
modulation on immune cells are wide-ranging and
context-dependent. Over the past decade, HIFs have
emerged as attractive targets for immunoregulation
and immunotherapy due to their ability to profoundly
influence immune cell behaviour and function, com-
bined with roles in regulating inflammatory pheno-
types in other cell types of the diseased tissue milieu.
Here, we explore recent developments that illuminate
HIFs’ roles in innate immunity and highlight HIF sig-
nalling components as therapeutic targets in multiple
disease settings.
HIFs’ effects on cellular innate
immunity
HIFs are key regulators of myeloid innate immune cell
function, influencing survival, migration and polarisa-
tion [9]. During infection and inflammation, HIF-a is
stabilised in immune cell populations, partially driven
by the hypoxic tissue context of disease, alongside oxy-
gen-independent activation [10].
Neutrophils are the first innate immune cell respon-
ders to wounds or infections in many disease contexts
and are exquisitely sensitive to low oxygen levels. HIF-
1a stabilisation increases the lifespan of neutrophils
Fig. 1. Genetic and pharmacological manipulation of HIF signalling. A schematic of intracellular regulation of the HIF-a subunit, with
normoxia on the left and hypoxia on the right. The therapeutic potential of targeting HIFs both genetically (orange text) and
pharmacologically (green text) has been facilitated by an emerging range of both inhibitory and activating compounds/techniques (listed
around the edge of the diagram). In normoxia (blue box), the HIF-a subunit is targeted for degradation. This can be prevented genetically
and pharmacologically via blocking initial hydroxylation by prolyl-hydroxylases (PHDs) or factor-inhibiting HIF (FIH), inhibiting Von Hippel–
Lindau (VHL) binding to HIF-a or reversing ubiquitination. In hypoxia (purple box), HIF-a is stabilised and translocates to the nucleus to bind
aryl hydrocarbon receptor nuclear translocator (ARNT) and cofactors p300 and CREB-binding protein (CBP) to transcribe downstream
targets. HIF-a transcription can be inhibited via targeting HIF-a directly using mutant animals/cells, by RNA-based approaches (e.g. siRNA),
or via blocking the nuclear accumulation of HIF-a or the dimerisation of HIF-a/ARNT complex.
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and their bactericidal capabilities in multiple experi-
mental models [11,12]. Neutrophil degranulation is an
important process in pathogen control, but can cause
extensive tissue damage when uncontrolled in chronic
inflammatory diseases where tissue hypoxia is often a
hallmark [13]. Human neutrophils in hypoxia have
augmented degranulation, while neutrophils with sta-
bilised HIF-a, after treatment with the pan hydroxy-
lase inhibitor, dimethyloxalylglycine (DMOG),
interestingly do not have the same increased degranu-
lation [14]. A dichotomy between physiological
hypoxia and HIF stabilisation is also observed in neu-
trophil extracellular trap (NET) formation, a mecha-
nism by which toxic components of the neutrophil
(including histones, neutrophil elastase and granules)
are ejected into the tissue microenvironment [15].
NETs have been implicated in the progression of mul-
tiple inflammatory conditions including chronic
obstructive pulmonary disease (COPD), asthma and
post-COVID-19 lung inflammation [16–18]. Neu-
trophils produce fewer NETs in hypoxic conditions,
due to NET formation requiring the oxygen-dependent
respiratory burst [15]. Hypoxia is even able to ablate
NET production when human blood-derived neu-
trophils are exposed to the most potent NET inducing
chemical, phorbol myristate acetate (PMA) [15]. How-
ever, HIF stabilisation in normoxia has been shown to
increase neutrophil NET formation through mam-
malian target of rapamycin (mTOR) [19]. These obser-
vations could be especially important in understanding
later stage COVID-19 infection, where NET formation
is predicted to play a major role in lung physiology
[18].
Macrophages are a key cellular component of innate
immunity, and like neutrophils, their function, migra-
tion and behaviours are influenced by hypoxia and
HIF signalling [20]. Alveolar macrophages from mye-
loid-specific VHL knockout (KO) mice possessing ele-
vated HIF-1a have increased pro-inflammatory
profiles, glycolytic enzyme activity and an abnormal,
foamy morphology [21]. HIF’s roles in metabolic
reprogramming of macrophages (and neutrophils), ter-
med immunometabolism, are an emerging field of
intense study in mice and humans 2122 that has been
extensively reviewed elsewhere in recent years [23–25].
Not only do HIFs regulate macrophage pro-inflamma-
tory profiles, but they also play emerging roles in regu-
lation of macrophage efferocytosis (clearance of
apoptotic neutrophils) and a switch in macrophage
polarisation towards ‘M2’-like, anti-inflammatory
states that allows restoration of tissue homoeostasis.
Macrophages from mice lacking HIF-2a had increased
efferocytosis compared to controls [26]. Myeloid HIF-
1a KO mice had attenuated anti-inflammatory profiles,
including a depressed arginase (ARG1) response, a key
anti-inflammatory macrophage enzyme [27]. HIF-2a
KO mice also have perturbed anti-inflammatory
macrophage cytokine profiles, with significantly lower
IL-6 (a liver protective cytokine) at mRNA and serum
levels in models of liver injury [23], although in other
disease situations IL-6 is associated with pro-inflam-
matory profiles [28]. Macrophage behaviours during
wound repair can be improved using HIF-directed
therapies. In a mouse model of chronic kidney disease,
the PHD inhibitor MK-8617 increased the infiltration
of macrophages into damaged muscle, improving mus-
cle repair and reducing muscle atrophy [29]. Addition-
ally, treatment of HIF-a inhibitor YC-1, in a mouse
injury model, decreased numbers of pro-inflammatory
macrophages in scar tissue and reduced levels of pro-
inflammatory cytokines in vivo [30]. These studies indi-
cate that macrophage HIF-targeted therapies could
allow a return to tissue homoeostasis after injury/in-
flammation.
Dampening HIF in chronic
inflammation
Chronic inflammation underpins diseases that are
characterised by a hyperinflammatory profile with
extensive immune cell-induced tissue damage. High
levels of hypoxia and HIF-1a are associated with
many of these conditions, including asthma, COPD,
rheumatoid arthritis (RA), colitis and atherosclerosis
[31–34]. Furthermore, HIF signalling interplays with
key inflammatory signalling pathways, including gluco-
corticoids, mTOR and arachidonic acid [35–37].
Targeting excessive HIF can be beneficial in the out-
come of chronic inflammatory diseases. In a mouse
model of asthma, suppression of HIF-1a with YC-1
reduced expression of IL-5, IL-13, myeloperoxidase
(MPO) and inducible nitric oxide synthase (iNOS),
which alleviated asthma symptoms [31]. In the highly
inflammatory, granulomatous condition of sarcoidosis,
downregulation of HIF-1a through genetic or pharma-
cological means reduced pro-inflammatory IL-1b, IL-
17 and IL-6 and improved disease outcomes [38].
However, downregulation of HIF-1a can also be detri-
mental in some inflammation-related conditions. HIF-
1a deficiency in B cells exacerbates collagen-induced
arthritis via impairment of IL-10 and B-cell expansion,
highlighting a need to target-specific immune cell sub-
sets [39]. Stabilising HIF-a subunits using hydroxylase
inhibitors has been shown to be beneficial in some
inflammatory conditions. DMOG suppresses the pro-
gression of periapical bone loss and attenuated
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inflammatory cell infiltration in apical periodontitis
[40]. DMOG was also beneficial in a rat ischaemia
model, reducing infarction size and increasing IL-4-
and IL-10-induced protection [41]. In a mouse model
of multiple sclerosis, the dual peroxisome proliferator-
activated receptor gamma (PPARc) and CB2 agonist,
VCE-004.8, was able to alleviate neuroinflammation
and demyelination through inhibition of pro-inflamma-
tory cytokines, via activation of HIF [42]. These anti-
inflammatory effects of HIF are emerging and are
likely to be a diseased tissue-specific effect. DMOG
treatment of macrophages directly increases expression
of pro-inflammatory factors such as iNOS and
decreases anti-inflammatory factors such as arginase
[43]. This can be highly detrimental in inflammatory
conditions. For example in an RA mouse model, HIF-
1a stabilisation with cobalt chloride (CoCl2), in combi-
nation with IL-17, is associated with increased disease
severity [44]. Stabilising HIF-a in inflammatory dis-
eases is therefore likely to be detrimental due to pro-
inflammatory effects, although tissue- and disease-
specific benefits may also occur.
Together these recent findings demonstrate the
potential of HIF regulation to treat chronic inflamma-
tory conditions through modulation of the myeloid
component. However, treatments that target HIF can
have pleiotropic effects, that differ in multiple cell
types that are present in disease tissue contexts, and
may require specific targeting.
Upregulating HIF in infections
Bacterial infections
Due to the hypoxic microenvironment of many bacte-
rial infections, combined with pathogen-associated
molecular pattern (PAMP)/TLR-induced HIF-a stabil-
isation, HIF has become increasingly associated with
innate immune control of infections (Fig. 2).
Tuberculosis (TB) has the highest mortality of any
single bacterial infection worldwide and has a complex
relationship with HIF, in part due to the hypoxic cen-
tres of hallmark granuloma structures. Mycobacterium
tuberculosis (Mtb) infection is associated with
increased HIF levels in immune cells, with peripheral
blood mononuclear cells (PMBCs) from human TB
patients producing high levels of HIF-1a, alongside
pro-inflammatory IL-17 and IL-1b when stimulated
with Mtb strain HN878 compared with healthy donors
[45]. Myeloid-specific HIF-1a KO mice have decreased
survival upon Mtb infection and larger areas of lung
inflammation, indicating that HIF-1a plays a pivotal
role in TB host defence [46]. Furthermore, HIF-1a KO
BMDMs have compromised lipid droplet formation,
sites of eicosanoid synthesis that are required for host
TB defence [47]. During early infection, HIF-1a stabil-
isation is beneficial for innate immune control of TB.
In a zebrafish TB model, using the fish-adapted patho-
gen and close genetic relative of Mtb, Mycobacterium
marinum (Mm), Hif-1a stabilisation increased myeloid
production of Il-1b, vital for decreasing bacterial bur-
den via neutrophil nitric oxide (NO) production
[48,49], alongside increasing pro-inflammatory macro-
phage Tnfa production [50]. The HIF-induced, host
NO response has also shown to be important in a
mouse model of TB infection, with HIF-1a and iNOS
in a positive feedback loop, balancing the inflamma-
tory phenotype [51]. However, too much HIF-1a dur-
ing later stage TB infection can be detrimental, as
HIF-1a regulators prevent excess inflammation and
host damage during active disease. IL-17 has been
shown to limit HIF-1a expression in a murine model,
with anti-IL-17 leading to an increased number of
HIF-1a-positive macrophages and larger TB lesions
[45]. Inhibition of HIF-1a in these anti-IL-17 mice
improved infection outcome, reducing granuloma size
and reversing excess inflammation [45]. Together these
recent data show critical roles of HIF-1a in both
innate immune cell TB control and in later stage gran-
uloma pathogenesis.
Recent studies have added to the large bulk of evi-
dence showing that HIF stabilisation is critical for the
control of multiple bacterial infections [52,53]. Heli-
cobacter pylori infection of human gastric tissue sta-
bilised HIF-1a but not HIF-2a, with HIF-2a
expression decreasing as disease severity increased [54].
HIF-1a was shown to be crucial for bacterial killing of
Helicobacter pylori as HIF-1a KO neutrophils pos-
sessed 66% more surviving bacteria, and KO macro-
phages had 5 times more surviving bacteria compared
to wild-type [54]. HIF-1a KO mice are also more sus-
ceptible to Listeria monocytogenes infection, possessing
higher bacterial burdens and more severe pathological
inflammation of the liver [55]. In a mouse model of
uropathogenic Escherichia coli (UPEC), stabilising
HIF-1a using the hydroxylase inhibitor AKB-4924
reduced bacterial burden by ~ 40% and attenuated the
virulence of a hyperinfective UPEC strain [56]. Inter-
estingly, activation of HIF-1a in this way reduced the
inflammatory profile in the murine bladder context,
another example of HIF-a stabilisation leading to
reduced inflammation. The bactericidal properties of
HIF-1a stabilisation have now been moved into clini-
cal settings, with promising results from CoCl2 con-
taining bandages, that not only prevented bacterial
survival and growth, but also promoted wound healing
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both in vitro and in vivo in a mouse infection model
[57]. These recent studies highlight how host HIF-1a
could be stabilised to improve bacterial infection out-
comes, particularly relevant due to rising occurrence of
multidrug-resistant bacterial strains.
Fungal infections
Fungal infections are an emerging global concern, and
recent studies have demonstrated important roles for
HIF in their pathogenesis. Myeloid HIF-1a KO mice
were more susceptible to Candida albicans infection
and have reduced NO and glycolytic activity [55]. Pro-
moting HIF-1a stabilisation with the hydroxylase inhi-
bitor CoCl2 promoted fungal death in vitro (human
macrophages) and in vivo (mouse) indicating a thera-
peutic potential for HIF-1a manipulation in candida
infection [55]. Activation of HIF-1a has even emerged
as being a natural mechanism by which commensal
bacteria inhibit Candida albicans colonisation in the
Fig. 2. The contribution of HIF-1a to infection outcomes. Figure showing the effects of HIF manipulation on bacterial, fungal and parasitic
infection outcomes. Generally, HIF-1a stabilisation is beneficial in the context of bacterial infections, for example Mycobacterium
tuberculosis/marinum (blue column); however, the level of HIF-1a must be carefully balanced, with too little or too much resulting in excess
inflammation and detrimental infection outcome. HIF-1a knockouts have decreases in IFNc [77], IL-1b [51] and IL-6 [51] leading to excess
tissue damage and lower survival [46]. Early HIF-1a stabilisation increases inflammatory factors leading to myeloid control of infection [48–
50], while excessive HIF-1a can lead to prolonged inflammation and larger TB lesions in later stage disease [51]. In the context of the fungal
infection Candida albicans (yellow column), HIF-1a knockout decreases pro-inflammatory factors while increasing anti-inflammatory IL-10
leading to increased fungal survival [55]. HIF-1a stabilisation improves infection outcome, re-arming the host inflammatory response leading
to increased fungal death [55,58]. In the parasitic infection Leishmania donovani (purple column), reducing HIF-1a improves infection
outcome, as the parasite itself upregulates host HIF-1a, and stabilised HIF-1a prevents CD8 + T-cell expansion, exacerbating the infection
further [62–64,78]. Each infection context is distinct, requiring a tailored and controlled HIF-a response that is not uniform across infections.
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gut [58]. Infection of myeloid-specific HIF-1a KO mice
with Histoplasma capsulatum had an increased anti-in-
flammatory macrophage signature, increased fungal
burden and decreased mouse survival, indicating
important roles of HIF in infection control 59. How-
ever, alveolar macrophage (AM)-specific HIF-1a KO
mice have comparable survival compared to WT, sug-
gesting a contribution from other cells of the myeloid
lineage [59]. These studies indicate an opportunity to
stabilise HIF-1a in hard-to-treat fungal infections.
However, as some fungi are capable of producing and
releasing their own proline hydroxylases, the effective-
ness of PHD inhibitors as a therapy remains unclear
[60].
Parasitic infections
Some parasitic infections are able to circumvent host
immunity by either failing to raise a pro-inflammatory
response or by mechanisms that actively reduce the
host pro-inflammatory response. Trypanosoma brucei
suppresses host HIF-1a through production of
indolepyruvate, a ketoacid reported to be a cofactor of
PHDs, promoting HIF-1a degradation [61]. Therefore,
in trypanosome infections it may be beneficial to sta-
bilise HIF-1a therapeutically. Conversely, Leishmania
donovani infection increases levels of HIF-1a, and
silencing HIF-1a in murine peritoneal macrophages
reduced both parasitic load and infectivity at 24 hours
postinfection [62]. BMDMs from HIF-1a-deficient
mice were more resistant to L. donovani infection,
expressed more ROS and were parasitised less com-
pared to wild-type [63]. However, a recent study has
shown that L. donovani-infected HIF-1a-deficient mice
developed hypertriglyceridemia and lipid accumulation
in splenic and hepatic myeloid cells, which impaired
host defence [64]. Together these studies suggest that
parasites are able to manipulate HIF-1a levels in a
variety of ways as part of their circumvention of the
host immune response, creating an opportunity to tar-
get HIF-1a to improve infection outcome that has yet
to be fully explored.
Future perspectives; targeting which
HIF-a, where?
Due to the complexity of innate immune contributions
to inflammatory and infectious diseases, targeting the
correct HIF proteins, in the correct cells, at the correct
time may be important considerations for any thera-
peutic strategy.
Recent in vitro and in vivo model studies described
here have largely focused on hydroxylase inhibition as
the potential HIF modulation therapy. The most suc-
cessful hydroxylase inhibitor in human trials is
Roxadustat (otherwise known as FG-4592). Roxadus-
tat has undergone phase 3 clinical trials for chronic
kidney disease-induced anaemia and was able to suc-
cessfully increase patient haemoglobin levels over a
prolonged 8-18 weeks period [65]. Other hydroxylase
inhibitors used in clinical trials of various stages in
recent years include the following: Molidustat [66],
Vadadustat (or AKB-6548) [67] and Daprodustat
(GSK1278863) [68]. Recently, a study has shown that
HIF-a stabilisation can also be achieved by intrabody
targeting of PHD2 [69]. HIF modulation via hydroxy-
lase inhibition stabilises all HIF-a isoforms, but there
are emerging methods to modulate HIF-a more
directly. PT2385 is a HIF-2a-specific inhibitor that has
been investigated in the first in-human safety study
and was shown to be well tolerated with a favourable
safety profile for patients with clear cell renal cell car-
cinoma (CCRCC) [70] and may open the way for
specific HIF-a isoform stabilisation in future therapies
against inflammatory diseases.
It is interesting to note that current clinical trials for
anaemia and CCRCC have used oral doses of HIF-
targeting drugs, without delivery to specific cell types
[65]. While there are no immediate indications that
whole body HIF drug delivery is detrimental in the
short term, this review highlights that in complex
inflammatory conditions targeting the wrong HIF-a
isoform in the wrong cell type could be detrimental to
disease outcome. For example, it was recently shown
in a model of chronic inflammation of the cornea
(Herpes Stromal Keratitis) that HIF-1a was high in
the myeloid lineage, whereas HIF-2a was higher in
epithelial cells, highlighting how different cell types in
close proximity regulate HIF signalling differently and
may need to be targeted separately in disease [71]. The
potential of HIF-1a stabilisation to contribute to
inflammatory and infectious comorbidities has recently
been explored in zebrafish models, where it was shown
that although Hif-1a stabilisation delays neutrophil
inflammation resolution, a host-protective effect
against mycobacterial infection remains [72]. A poten-
tially important step in immunoregulatory therapies
would be cell-specific targeting of HIF drugs in a
timely way. Drug delivery methods, such as pH-sensi-
tive liposomes and liquid emulsion systems, have been
used for timely delivery of HIF-targeting drugs to
specific tissues in animal models of disease [73,74].
Emerging technologies, such as synthetic polymer-
somes that are preferentially taken up by innate
immune cells, could be employed to deliver HIF-tar-
geted drugs to myeloid cells during infection and
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inflammation [75]. Gene therapy methods have also
been explored, with nanoparticle delivery of siRNA
for HIF-1a used to genetically manipulate HIF in a
murine model of hypoxic tumour growth [76].
In conclusion, hypoxia and HIF stabilisation are hall-
mark characteristics of progressed tissue inflammation
and infection. The effects of HIF modulation on the
innate immune response are profound, with recent find-
ings illustrating that HIF’s effects can be complex and
disease-specific. Studies in in vitro and in vivo models
indicate that HIF modulation during inflammation and
infections may be promising therapeutic strategies
against these hard-to-treat diseases. Subtle fine-tuning
of the innate immune system via HIF manipulation to
achieve a balance between protection against pathogens
and hyperinflammation will be an important considera-
tion to develop future therapies that target host immune
cells during diseases of inflammation and infection.
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